Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126059634 | 12605963 | 4 | F | 20160408 | 20160915 | 20160729 | 20160919 | PER | US-PFIZER INC-2016332940 | PFIZER | 65.00 | YR | F | Y | 99.77000 | KG | 20160919 | PH | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126059634 | 12605963 | 1 | PS | AROMASIN | EXEMESTANE | 1 | Oral | 25 MG, 1X/DAY (Q DAY) (30 DAYS) | 20753 | 25 | MG | COATED TABLET | QD | ||||||
| 126059634 | 12605963 | 2 | SS | AROMASIN | EXEMESTANE | 1 | 25 MG, DAILY | 20753 | 25 | MG | COATED TABLET | ||||||||
| 126059634 | 12605963 | 3 | SS | AFINITOR | EVEROLIMUS | 1 | Oral | 7.5 MG, DAILY | Y | 0 | 7.5 | MG | TABLET | ||||||
| 126059634 | 12605963 | 4 | SS | AFINITOR | EVEROLIMUS | 1 | Oral | 5 MG, 1X/DAY (Q DAY) | Y | 0 | 5 | MG | TABLET | QD | |||||
| 126059634 | 12605963 | 5 | SS | AFINITOR | EVEROLIMUS | 1 | Oral | 10 MG, 1X/DAY | Y | 0 | 10 | MG | TABLET | QD | |||||
| 126059634 | 12605963 | 6 | SS | AFINITOR | EVEROLIMUS | 1 | Oral | 5 MG, DAILY | Y | 0 | 5 | MG | TABLET | ||||||
| 126059634 | 12605963 | 7 | C | ALLEGRA | FEXOFENADINE HYDROCHLORIDE | 1 | 180 MG, AS NEEDED | 0 | 180 | MG | TABLET | ||||||||
| 126059634 | 12605963 | 8 | C | BIOTIN | BIOTIN | 1 | 7500 UG, 1X/DAY | 0 | 7500 | UG | TABLET | QD | |||||||
| 126059634 | 12605963 | 9 | C | BUTALBITAL AND ACETAMINOPHEN | ACETAMINOPHENBUTALBITAL | 1 | UNK (BUTALBITAL 50 MG-ACETAMINOPHEN 325 MG) (AS DIRECTED) | 0 | TABLET | ||||||||||
| 126059634 | 12605963 | 10 | C | CALTRATE WITH VITAMIN D | CALCIUM CARBONATECHOLECALCIFEROL | 1 | UNK UNK, 1X/DAY (CALTRATE 600 +D 600-400 MG) | 0 | TABLET | QD | |||||||||
| 126059634 | 12605963 | 11 | C | CLOTRIMAZOLE. | CLOTRIMAZOLE | 1 | UNK (1 %) | 0 | CREAM | ||||||||||
| 126059634 | 12605963 | 12 | C | COREG | CARVEDILOL | 1 | 12.5 MG, 1X/DAY | 0 | 12.5 | MG | TABLET | QD | |||||||
| 126059634 | 12605963 | 13 | C | ENALAPRIL MALEATE. | ENALAPRIL MALEATE | 1 | 10 MG, 1X/DAY | 0 | 10 | MG | TABLET | QD | |||||||
| 126059634 | 12605963 | 14 | C | FLAXSEED | FLAX SEED | 1 | 1000 MG, 1X/DAY | 0 | 1000 | MG | CAPSULE | QD | |||||||
| 126059634 | 12605963 | 15 | C | FUROSEMIDE. | FUROSEMIDE | 1 | 40 MG, UNK | 0 | 40 | MG | TABLET | ||||||||
| 126059634 | 12605963 | 16 | C | LIPITOR | ATORVASTATIN CALCIUM | 1 | 40 MG, 1X/DAY | 0 | 40 | MG | TABLET | QD | |||||||
| 126059634 | 12605963 | 17 | C | NAPROXEN. | NAPROXEN | 1 | 375 MG, 2X/DAY (EVERY 12 HOURS, 15 DAYS) | 0 | 375 | MG | TABLET | BID | |||||||
| 126059634 | 12605963 | 18 | C | NEURONTIN | GABAPENTIN | 1 | 100 MG, UNK (AS DIRECTED) | 0 | 100 | MG | CAPSULE | ||||||||
| 126059634 | 12605963 | 19 | C | NITROGLYCERIN. | NITROGLYCERIN | 1 | 0.4 MG, AS NEEDED (0.4 MG/SPRAY SOLN) | 0 | .4 | MG | |||||||||
| 126059634 | 12605963 | 20 | C | PRADAXA | DABIGATRAN ETEXILATE MESYLATE | 1 | 150 MG, 2X/DAY | 0 | 150 | MG | CAPSULE | BID | |||||||
| 126059634 | 12605963 | 21 | C | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | 50 MG, 1X/DAY | 0 | 50 | MG | TABLET | QD | |||||||
| 126059634 | 12605963 | 22 | C | TIZANIDINE HCL | TIZANIDINE HYDROCHLORIDE | 1 | 2 MG, UNK (AS DIRECTED) | 0 | 2 | MG | CAPSULE | ||||||||
| 126059634 | 12605963 | 23 | C | TRAMADOL + ACETAMINOFEN | 2 | UNK (TRAMADOL37.5 MG-ACETAMINOPHEN 325MG) | 0 | TABLET | |||||||||||
| 126059634 | 12605963 | 24 | C | XOPENEX | LEVALBUTEROL HYDROCHLORIDE | 1 | UNK (0.63 MG/3ML NEBU) (AS DIRECTED) | 0 | |||||||||||
| 126059634 | 12605963 | 25 | C | XOPENEX HFA | LEVALBUTEROL TARTRATE | 1 | UNK (45 MCG/ACT AERO) (AS DIRECTED) | 0 | |||||||||||
| 126059634 | 12605963 | 26 | C | NAPROSYN | NAPROXEN | 1 | 375 MG, 2X/DAY (FOR 15 DAYS) | 0 | 375 | MG | BID | ||||||||
| 126059634 | 12605963 | 27 | C | SYMBICORT | BUDESONIDEFORMOTEROL FUMARATE DIHYDRATE | 1 | UNK, 160-4.5 MCG/ACT AERO, AS DIRECTED) | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126059634 | 12605963 | 1 | Breast cancer |
| 126059634 | 12605963 | 2 | Breast cancer female |
| 126059634 | 12605963 | 3 | Breast cancer |
| 126059634 | 12605963 | 26 | Pain |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126059634 | 12605963 | Anal incontinence | |
| 126059634 | 12605963 | Arthralgia | |
| 126059634 | 12605963 | Asthenia | |
| 126059634 | 12605963 | Decreased appetite | |
| 126059634 | 12605963 | Diarrhoea | |
| 126059634 | 12605963 | Dyspnoea | |
| 126059634 | 12605963 | Fatigue | |
| 126059634 | 12605963 | Frequent bowel movements | |
| 126059634 | 12605963 | Gait disturbance | |
| 126059634 | 12605963 | Haematoma | |
| 126059634 | 12605963 | Headache | |
| 126059634 | 12605963 | Lymphocyte count decreased | |
| 126059634 | 12605963 | Neutrophil count decreased | |
| 126059634 | 12605963 | Platelet count decreased | |
| 126059634 | 12605963 | Rash | |
| 126059634 | 12605963 | Skin discolouration | |
| 126059634 | 12605963 | Weight decreased | |
| 126059634 | 12605963 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126059634 | 12605963 | 2 | 20160322 | 0 | ||
| 126059634 | 12605963 | 3 | 20160317 | 0 | ||
| 126059634 | 12605963 | 6 | 201603 | 0 |